PROCEPT BioRobotics Co. (NASDAQ:PRCT) Shares Acquired by Occudo Quantitative Strategies LP

Occudo Quantitative Strategies LP raised its position in PROCEPT BioRobotics Co. (NASDAQ:PRCT - Free Report) by 145.7% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 8,671 shares of the company's stock after purchasing an additional 5,142 shares during the quarter. Occudo Quantitative Strategies LP's holdings in PROCEPT BioRobotics were worth $698,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in the company. Raleigh Capital Management Inc. bought a new position in shares of PROCEPT BioRobotics during the fourth quarter valued at approximately $32,000. Thematics Asset Management purchased a new position in PROCEPT BioRobotics during the 4th quarter valued at $46,000. Signaturefd LLC boosted its holdings in PROCEPT BioRobotics by 26.7% during the 4th quarter. Signaturefd LLC now owns 689 shares of the company's stock valued at $55,000 after acquiring an additional 145 shares during the period. IFP Advisors Inc bought a new position in PROCEPT BioRobotics in the 4th quarter valued at $58,000. Finally, Arcadia Investment Management Corp MI purchased a new stake in PROCEPT BioRobotics in the fourth quarter worth $64,000. Institutional investors own 89.46% of the company's stock.

PROCEPT BioRobotics Stock Down 0.3%

NASDAQ:PRCT traded down $0.17 during mid-day trading on Tuesday, reaching $59.13. The company's stock had a trading volume of 144,792 shares, compared to its average volume of 814,296. The company has a quick ratio of 5.07, a current ratio of 6.02 and a debt-to-equity ratio of 0.21. PROCEPT BioRobotics Co. has a 1 year low of $47.04 and a 1 year high of $103.81. The stock has a fifty day moving average of $55.25 and a 200-day moving average of $71.54. The firm has a market capitalization of $3.27 billion, a PE ratio of -30.35 and a beta of 1.10.

PROCEPT BioRobotics (NASDAQ:PRCT - Get Free Report) last posted its quarterly earnings results on Thursday, April 24th. The company reported ($0.45) EPS for the quarter, beating the consensus estimate of ($0.49) by $0.04. PROCEPT BioRobotics had a negative net margin of 50.07% and a negative return on equity of 38.57%. The business had revenue of $69.16 million during the quarter, compared to analyst estimates of $65.39 million. During the same quarter in the previous year, the business posted ($0.51) EPS. The company's quarterly revenue was up 55.5% compared to the same quarter last year. Equities research analysts forecast that PROCEPT BioRobotics Co. will post -1.75 earnings per share for the current year.

Analysts Set New Price Targets

A number of analysts have recently issued reports on PRCT shares. Truist Financial lowered their target price on shares of PROCEPT BioRobotics from $90.00 to $70.00 and set a "buy" rating for the company in a research note on Friday, April 11th. Morgan Stanley decreased their price objective on shares of PROCEPT BioRobotics from $105.00 to $95.00 and set an "overweight" rating for the company in a report on Wednesday, February 26th. Finally, Bank of America dropped their target price on shares of PROCEPT BioRobotics from $104.00 to $84.00 and set a "buy" rating on the stock in a research note on Friday, April 25th. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat, PROCEPT BioRobotics presently has an average rating of "Moderate Buy" and a consensus target price of $90.00.

Insiders Place Their Bets

In other PROCEPT BioRobotics news, CEO Reza Zadno sold 5,475 shares of the business's stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $57.06, for a total value of $312,403.50. Following the completion of the transaction, the chief executive officer now directly owns 173,070 shares in the company, valued at approximately $9,875,374.20. The trade was a 3.07% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CFO Kevin Waters sold 733 shares of the stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $57.06, for a total transaction of $41,824.98. Following the sale, the chief financial officer now directly owns 107,991 shares of the company's stock, valued at approximately $6,161,966.46. The trade was a 0.67% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 6,455 shares of company stock worth $368,322 over the last 90 days. Company insiders own 6.60% of the company's stock.

About PROCEPT BioRobotics

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).